SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-03-23
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2021-03-31 was 0.60%, a 25.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-03-31 was 0.80%, a 66.67% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-03-31 was 2.40%, a 11.76% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-03-31 was 2.72%.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.50%, a 0.00% change from fiscal 2024.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.50%, a 2.78% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.60%, a 111.76% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.70%, a 183.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 3.50% 10-K · filed 2026-03-23 | |||||||
| 2024-12-31 | 3.50% 10-K · filed 2026-03-23 | |||||||
| 2023-12-31 | 3.60% 10-K · filed 2025-03-13 | |||||||
| 2022-12-31 | 1.70% 10-K · filed 2025-03-13 | |||||||
| 2022-06-30 | 1.70% 10-Q · filed 2022-08-08 | |||||||
| 2021-12-31 | 0.60% 10-K · filed 2024-03-25 | |||||||
| 2021-09-30 | 0.60% 10-Q · filed 2021-11-10 | |||||||
| 2021-06-30 | 0.60% 10-Q · filed 2022-08-08 | |||||||
| 2021-03-31 | 0.60% 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | 0.20% 10-K · filed 2023-03-30 | |||||||
| 2020-09-30 | 0.20% 10-Q · filed 2021-11-10 | 0.16% 10-Q · filed 2020-11-05 | ||||||
| 2020-06-30 | 0.20% 10-Q · filed 2021-08-09 | 0.16% 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | 0.80% 10-Q · filed 2021-05-07 | 0.79% 10-Q · filed 2020-05-11 | ||||||
| 2019-12-31 | 1.40% 10-K · filed 2022-02-28 | 1.42% 10-K · filed 2020-03-16 | ||||||
| 2019-09-30 | 1.42% 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | 1.85% 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 2.40% 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | 2.70% 10-K · filed 2021-03-18 | 2.67% 10-K · filed 2019-04-01 | ||||||
| 2018-09-30 | 2.72% 10-Q · filed 2019-11-08 | |||||||
| 2018-06-30 | 2.72% 10-Q · filed 2019-08-14 | |||||||
| 2018-03-31 | 2.72% 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | 1.89% 10-K · filed 2020-03-16 | |||||||
| 2017-09-30 | 1.89% 10-Q · filed 2018-11-14 | |||||||
| 2016-12-31 | 1.24% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |